$FRBN News
Last published 3y ago
- 3y agoENGNFRBNenGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines CompanyPR NewswireBusiness combination transaction completed with Forbion European Acquisition Corp. Clinical stage biotechnology company with EG-70 lead program in...
- 3y agoFRBNenGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical OfficerPR NewswireBOSTON and MONTREAL, Sept. 7, 2023 /CNW/ - enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other organs,
- 3y agoFRBNenGene, Inc. and Forbion European Acquisition Corp. ("FEAC", Nasdaq: FRBN) Announce Business Combination Agreement to Create Nasdaq-Listed Biotechnology Company Developing Next-Generation Non-Viral, Locally Administered Gene TherapiesGlobeNewswireLeading institutional investors commit $135 million USD in transaction financing, anchored by FEAC's sponsor, Forbion Growth Sponsor FEAC I B.V. (together with its parent entity Forbion Growth Opportunities Fund I
- 3y agoFRBNNAMSVECTVectivBio Announces Results of Extraordinary General MeetingGlobeNewswireBASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare